Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…
Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left…
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of…
Merus Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NonSmall Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
BIZENGRI® is the first and only therapy approved by the FDA specifically…